



DISTRIBUTOR AGREEMENTS

PERTH, 28th May 2010. HELICON GROUP LIMITED (ASX: HCG) today announced that it has agreed with Avita Medical Ltd to cancel its distributor agreements for ReCELL® in China and Hong Kong.

Helicon successfully gained regulatory approval in China for ReCELL® the leading edge autologous skin harvesting device, in August 2009. The Chinese Regulatory Authority subsequently requested clinical evaluations as part of a listing process to gain pricing approval for sale of the product. The Company has concluded that its distributor margin could not justify funding the product through this process.

FUTURE DIRECTION

Helicon is in advanced stages of negotiation on a number of alternatives for its future direction and will make an announcement in due course.

DIRECTOR STATUS

Mr Peter Abrahamson, the Company's Managing Director, has moved to non-executive director status.

Ends

For further information please contact:

Peter Abrahamson
Helicon Group Limited
Suite 3, 257 York Street,
Subiaco WA 6006
Tel: +61 411 336 330
Email: peter@helicongroup.com.au
Website: www.helicongroup.com.au